IMNN
Imunon, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.99
−3.43%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.99
From 52W high−80.65%
Volume93789.00
Market cap$5.53M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.99
From 52W high
−80.65%
Volume
93789.00
Market cap
$5.53M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
P/E (TTM)
—
RSI (14)
25.0
MomentumView details →
1D Return
−3.43%
YTD Return
−73.75%
SummaryUpdated Jun 1, 2026
Imunon, Inc. (NASDAQ:IMNN) is a clinical-stage biotechnology company founded in 1982 and headquartered in Lawrenceville, New Jersey. Originally known as Celsion Corporation, the company rebranded to Imunon in September 2022 to better reflect its focus on immunotherapy development. The company has been publicly traded since 1999 and specializes in developing DNA-based immunotherapies and vaccines for cancer treatment and infectious diseases. Imunon operates two primary technology platforms and is currently advancing its lead ovarian cancer treatment through Phase III clinical trials while exploring partnerships for its vaccine technologies.
Similar companies
Latest newsMore news →
Imunon, Inc. exchanged $1.2 million of its Secured Promissory Note A-1 for 120 shares of Series B Preferred Stock at $10,000 per share with Streeterville Capital, LLC.21d agoIMUNON announced that an Independent Data Monitoring Committee recommended continuing Phase 2 development of IMNN-001 without modification following a favorable safety review of the ongoing MRD study.28d agoImunon entered a Cooperative Research and Development Agreement with the National Cancer Institute's Cancer Therapy Evaluation Program to advance clinical development of IMNN-001 in new indications and combination regimens.40d ago